Showing 6481-6490 of 10548 results for "".
- Phase 3 PSOARING 3 Long-Term Extension Study Data Positive for Tapinarof Creamhttps://practicaldermatology.com/news/phase-3-psoaring-3-long-term-extension-study-data-positive-for-tapinarof-cream/2461251/New data from the one-year safety and efficacy final analyses of the Phase 3 PSOARING 3 long-term, open-label extension (“LTE”) study of Dermavant Sciences' VTAMA (tapinarof) cream, 1% for the treatment of plaque psoriasis in adults was published in the
- Researchers ID Sensor Underlying Mechanical Itchhttps://practicaldermatology.com/news/researchers-id-sensor-underlying-mechanical-itch/2461248/Scientists at Scripps Research have identified a protein in sensory nerves that works as a key detector of the “mechanical” itch stimulus of crawling insects, wool fibers, or other irritating objects that touch the skin. The discovery, published June 22, 2022, in Nature
- Cool News on Ice-slurry Injections for Subcutaneous Body Fat Reductionhttps://practicaldermatology.com/news/cool-news-on-ice-slurry-injections-is-for-subcutaneous-body-fat-reduction/2461247/Cryolipolysis with injectable ice-slurry may soon become an efficient, effective and customizable method of body sculpting, according to new research ine Lasers in Surgery and Medicine. Our siste
- TruSkin SPF 30 Mineral Sunscreen with Vitamin C Launcheshttps://practicaldermatology.com/news/truskin-spf-30-mineral-sunscreen-with-vitamin-c-launches/2461245/New from TruSkin, TruSkin SPF 30 Mineral Sunscreen with Vitamin C features non-nano zinc oxide in a lightweight, non-greasy formula with asheer finish intended to blend into a
- The Aeshetic Show: Organizers Highlight Top Reasons to Attendhttps://practicaldermatology.com/news/the-aeshetic-show-organizers-highlight-top-reasons-to-attend/2461244/Unique in its multidisciplinary approach, The Aesthetic Show has, for more that 15 years, covered the rapidly-expanding field of aesthetic medicine. Attendees can unite with contemporaries across various medical disciplines, learn trailblazing techniques, and discover the groundbreaking solutions
- ProofPilot Wants You to Submit Research Ideas on Issues Concerning BIPOC Communitieshttps://practicaldermatology.com/news/proofpilot-wants-you-to-submit-research-ideas-on-issues-concerning-bipoc-communities/2461237/ProofPilot, a Software as a Service (SaaS) clinical trial research platform, is rolling out its first ever Open Invitation for Research, in partnership with the nonprofit organization
- Vial Dermatology CRO adds Dr. Jonathan Zung to Scientific Advisory Boardhttps://practicaldermatology.com/news/vial-dermatology-cro-adds-dr-jonathan-zung-to-scientific-advisory-boar/2461236/The Vial Dermatology CRO welcomed Jonathan Zung, PhD, as the newest addition to the Vial Scientific Advisory Board. Dr. Zung will support the Vial CRO team and their sponsors to further advance the field of dermatology clinical researc
- Senté Launches Even Tone Mineral Sunscreenhttps://practicaldermatology.com/news/sente-launches-even-tone-mineral-sunscreen/2461230/Senté has launched Even Tone Mineral Sunscreen. The new tinted sunscreen formulas protect the skin from damage caused by visible light in addition to UV rays and are specifically designed to promote even skin tone in every complexion, the company says.
- New Research Reveals Roughly 4 in 5 Acne Sufferers Have Missed Moments in Their Life Due to Acnehttps://practicaldermatology.com/news/new-research-reveals-roughly-4-in-5-acne-sufferers-have-missed-moments-in-their-life-due-to-acne/2461227/Ninety percent of moderate to severe acne sufferers said having acne-free skin would dramatically change the way they live their life, according to a new survey released today. The survey was conducted on behalf of Cutera, Inc., which offers AviClear, the first
- Eight out of Ten Patients Maintained Skin Clearance at One Year in Lilly's Lebrikizumab Atopic Dermatitis Monotherapy Trialshttps://practicaldermatology.com/news/eight-out-of-ten-patients-maintained-skin-clearance-at-one-year-in-lillys-lebrikizumab-atopic-dermatitis-monotherapy-trials/2461223/Fully 80 percent of lebrikizumab responders maintained improvements in skin clearance and atopic dermatitis disease severity at 52 weeks with once every two week and once every four week maintenance dosing, according to topline results from the Phase 3 clinical trials (ADvocate 1 a